Benign metastasizing leiomyoma (BML): A retrospective case series analysis of 8 patients (pts).

医学 子宫切除术 转移瘤切除术 外科 相伴的 曲普瑞林 平滑肌瘤 内科学 转移 癌症 激素 促黄体激素 促性腺激素释放激素
作者
Vittoria Colia,Angelo Paolo Dei Tos,Elena Fumagalli,Rossella Bertulli,Domenica Lorusso,Francesco Raspagliesi,Carlo Morosi,Maria Luisa Carcangiu,Paolo G. Casali,Roberta Sanfilippo
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:35 (15_suppl): e22525-e22525 被引量:2
标识
DOI:10.1200/jco.2017.35.15_suppl.e22525
摘要

e22525 Background: BML is a rare entity marked by the presence of lung lesions in women with a history of surgery for a benign leiomyoma of the uterus. Optimal treatment strategy for BML is poorly defined. We report on the activity of systemic therapy in a retrospective series of pts with BML. Methods: Cases diagnosed with BML from June 1993 to January 2017 at Istituto Nazionale Tumori, Milan, were reviewed. Results: Eight pts were identified, with a median age of 43 yrs. Estrogen and progesteron receptors were positive in all cases. All pts underwent surgery (3 hysterectomy, 2 myomectomy, 2 hysteroannessiectomy and 1 left ovariectomy) for suspected uterine leiomyoma (1 leg; 1 thigh); 2 pts had concomitant lung disease. 8 pts developed lung metastases and 2 had also limb metastases. 2 pts underwent lung metastasectomy, followed by watchful waiting with CT every 6 mos and were disease-free at their last follow up after 132 mos and 84 mos from diagnosis. 6 pts received systemic therapy for progressing advanced disease (1-6 lines). Among 6 pts treated, 2 were in fertility age and underwent ovary-sparing hysterectomy, receiving GnRH agonist with 1 PR lasting 96 mos and 1 SD lasting 38 mos; 2 pts received an aromatase inhibitor with 1 PR lasting 24 mos and 1 SD lasting 12 mos; 2 pts received oral estrogens with 1 PR lasting 39 mos and 1 SD lasting 2 mos; 1 pt received oral progestins with a PR lasting 12 mos; 3 patients received antracyclin +/- ifosfamide obtaining 2 PR after 3 cycles (cys) and 1 SD after 3 cys lasting 6 mos; 1 pt received high-dose ifosfamide with a PR after 5 cys; 1 pt received ifosfamide+dacarbazine obtaining a CR after 6 cys; 2 pts received gemcitabine with 1 PR after 3 cys and 1 SD after 2 cys lasting 6 mos; 1 pt received oral etoposide with a PR lasting 21 mos; 1 pt received sorafenib with a SD lasting 6 mos; 1 pt received everolimus with a PR lasting 57 mos. In this case, everolimus was discontinued due to lung toxicity. No pts progressed during treatment. At a median follow-up of 55 mos, 6 pts are alive, while 2 are dead of disease. Conclusions: In a series of 8 pts, we confirm the activity of hormonal treatment in BML. mTOR inihibitors or chemotherapy also show to be active.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro发布了新的文献求助10
1秒前
陶军辉发布了新的文献求助10
2秒前
2秒前
2秒前
qym完成签到,获得积分10
3秒前
淡然的冰海完成签到,获得积分10
3秒前
稳重蜗牛完成签到,获得积分10
3秒前
3秒前
zxc完成签到,获得积分10
3秒前
4秒前
shawn发布了新的文献求助10
4秒前
小丸子完成签到,获得积分10
4秒前
siwen发布了新的文献求助10
4秒前
心灵美的大山完成签到,获得积分10
4秒前
jackie发布了新的文献求助10
5秒前
三黑猫应助拼搏的不评采纳,获得10
5秒前
5秒前
6秒前
zq1992nl完成签到,获得积分10
6秒前
6秒前
小马甲应助zhouchen采纳,获得10
6秒前
深情安青应助ren采纳,获得10
6秒前
小镇青年发布了新的文献求助10
6秒前
chen发布了新的文献求助10
7秒前
我不李解发布了新的文献求助10
7秒前
8秒前
8秒前
9秒前
不配.应助ark861023采纳,获得10
9秒前
kk发布了新的文献求助10
10秒前
Jasper应助路茉采纳,获得10
10秒前
11秒前
jiabao完成签到,获得积分10
11秒前
在水一方应助畅快的文龙采纳,获得10
11秒前
123发布了新的文献求助10
12秒前
脚啊啊啊完成签到,获得积分10
12秒前
1111完成签到,获得积分20
12秒前
Junanne完成签到,获得积分10
13秒前
qqqq发布了新的文献求助10
13秒前
红红酱发布了新的文献求助10
13秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3082132
求助须知:如何正确求助?哪些是违规求助? 2735334
关于积分的说明 7536806
捐赠科研通 2384951
什么是DOI,文献DOI怎么找? 1264558
科研通“疑难数据库(出版商)”最低求助积分说明 612673
版权声明 597623